WO WO2010111367A1
· 2010
[cited by applicant]
WO WO2010151792
· 2010
[cited by applicant]
WO WO2015013671A1
· 2015
[cited by applicant]
WO WO2015100366
· 2015
[cited by applicant]
WO WO2015127158A1
· 2015
[cited by applicant]
WO 2015148708A1
· 2015
[cited by applicant]
WO WO2016105450
· 2016
[cited by applicant]
WO WO2016173605A1
· 2016
[cited by applicant]
WO WO2017134197A1
· 2017
[cited by examiner]
WO WO2017218707A2
· 2017
[cited by applicant]
WO 2018045110A1
· 2018
[cited by applicant]
WO WO2018090052
· 2018
[cited by applicant]
WO WO2019005640A2
· 2019
[cited by applicant]
WO 2019212965A1
· 2019
[cited by applicant]
WO WO2021091953
· 2021
[cited by applicant]
Lloyd et al., Protein Engineering, Design & Selection 22:159-168 (Year: 2009).
[cited by examiner]
Edwards et al., J Mol Biol. Nov. 14, 2003;334(1): 103-118 (Year: 2003).
[cited by examiner]
Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522-527 (Year: 2008).
[cited by examiner]
Piche-Nicholas et al., MABS 10(1): 81-94 (Year: 2018).
[cited by examiner]
Stancovski et al., PNAS, 88: 8691-8695 (Year: 1991).
[cited by examiner]
Cochran et al., J. Immunol. Meth. 287: 147-158 (Year: 2004).
[cited by examiner]
Bates et al., 2019, “David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments,” Antibodies 8(28):2-3188.
[cited by applicant]
Chiu et al., 2016, “Engineering Antibody Therapeutics,” Current Opinion in Structural Biology 38:163-173.
[cited by applicant]
Cuesta et al., 2010, “Multivalent Antibodies: When Design Surpasses Evolution,” Trends in Biology 28(7):355-362.
[cited by applicant]
De Goei et al., 2016, “Efficient Payload Delivery by a Bispecific Anti-body Drug Conjugate Targeting HER2 and CD63” Mol Cancer Ther. 15(11):2688-2697.
[cited by applicant]
Dimasi et al., 2019, “Molecular Engineering Strategies and Methods for the Expression and Purification of IgG1-Based Bispecific Bivalent Antibodies,” Methods 154: 77-86.
[cited by applicant]
Elgundi et al., 2017, “The State-of-play and Future of Antibody Therapeutics,” Advanced Drug Delivery Reviews 122:2-19.
[cited by applicant]
Gu et al., 2010, “Rationale and Development of Multispecific Antibody Drugs,” Expert Review of Clinical Pharmacology 1-2.
[cited by applicant]
Ha et al., 2016, “Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins,” Frontiers in Immunology 7:1-16.
[cited by applicant]
Huang et al., 2016, “Bispecific Antibody Case Studies,” Lake Pharma: The Biologics Company, PowerPoint 1-28.
[cited by applicant]
Husain et al., 2018, “Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies” Biodrugs 32(5):441-464.
[cited by applicant]
Kareva et al., 2018, “Guiding Principles for Mechanistic Modeling of Bispecific Antibodies,” ScienceDirect 139:59-72.
[cited by applicant]
Klein et al., 2019, “Engineering Therapeutic Bispecific Antibodies Using CrossMab Technology,” Methods 154:21-31.
[cited by applicant]
Koch et al., 2017, “Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy,” Transfusion Medicine and Hemotherapy 44:337-350.
[cited by applicant]
Kontermann et al., 2012, “Dual Targeting Strategies with Bispecific Antibodies,” mAbs 4(2):182-197.
[cited by applicant]
Kontermann et al., 2015, “Bispecific Antibodies,” Drug Discovery Today 20(7):838-847.
[cited by applicant]
Labrijn et al., 2019, “Bispecific Antibodies: a Mechanistic Review of the Pipeline,” Nature Reviews Drug Discovery 1-24.
[cited by applicant]
Liu et al., 2017, “Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds,” Frontiers in Immunology 8(38): 1-15.
[cited by applicant]
Mertens, Nico, 2011, “Tribodies: Fab-scFv Fusion Proteins as a Platform to Create Multi-functional Pharmaceuticals,” Bispecific Antibodies 135-149.
[cited by applicant]
Middleburg et al., 2021, “Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors,” Cancers 13(287):1-25.
[cited by applicant]
Moore et al., 2019, “A Robust Heterodimeric Fc Platform Engineered for Efficient Development of Bispecific Antibodies of Multiple Formats,” Methods 154:38-50.
[cited by applicant]
Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2020/058798 dated Feb. 23, 2021, including Internationa…
[cited by applicant]
Nyakatura et al., 2018, “Design and Evaluation of Bio and Trispecific Antibodies Targeting Multiple Filovirus Glycoproteins,” JBC Papers 1-19.
[cited by applicant]
Padte et al., 2018, “Engineering Multi-specific Antibodies Against HIV-1,” Retrovirology 15(60):1-17.
[cited by applicant]
Runcie et al., 2018, “Bi-specific and Tri-specific Antibodies- the Next Big Thing in Solid Tumor Therapeutics,” Molecular Medicine 24(50):1-15.
[cited by applicant]
Schanzer et al., 2014, “A Novel Glycoengineering Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique…
[cited by applicant]
Smith et al., 2015, “A Novel, Native-format Bispecific Antibody Triggering T-cell Killing of B-cells is Robustly Active in Mouse Tumor Models and Cynomolgus Monkeys,” Scientific Reports 5(17943):1-12.
[cited by applicant]
Spiess et al., 2015, “Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies,” Molecular Immunology 67:95-106.
[cited by applicant]
Steinmetz et al., 2016, “COVG-Ig, a Universal Bispecific Tetravalent and Multifunctional Immunoglobulin Format for Medical Applications,” mAbs 8(5): 867-878.
[cited by applicant]
Surguladze et al., 2019, “LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions” Cancer Res. 79(13S):4835.
[cited by applicant]
Weidle et al., 2013, “The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer,” Cancer Genomics & Proteomics 10: 1-18.
[cited by applicant]
Weidle et al., 2014, “Tumor-Antigen-Binding Bispecific Antibodies for Cancer Treatment,” Seminars in Oncology 41(5):653-660.
[cited by applicant]
Wu et al., 2015, “Fab-based Bispecific Antibody Formats with Robust Biophysical Properties and Biological Activity,” mAbs 7(3):470-482.
[cited by applicant]
Wu et al., 2019, “Building Blocks for Bispecific and Trispecific Antibodies,” Methods 154:3-9.
[cited by applicant]
Yang et al., 2020, “Alternative format bispecific antibodies targeting multiple oncogenic FGFR3 mutations in bladder cancer through different mechanisms” Cancer Res. 80(16S):526.
[cited by applicant]
You et al., 2021, “Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies,” Vaccines 724:1-28.
[cited by applicant]
Edwards et al., 2003 “The Remarkable Flexibility of the Human Antibody Repertoire; Islocation of Over One Thousand Different Antibodies to a Single Protein, BLyS” J. Mol. Biol. 334: 103-118.
[cited by applicant]
Lloyd et al., 2008 “Modelling the human immune response: performance of a 10″ human antibody repertoire against a broad panel of therapeutically relevant antigens” Protein Engineering, Design & Selectioni, 22(3): 159-16…
[cited by applicant]
Piche-Nicholas et al., 2018 “Changes in complementary-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics” MABS 10(1): 81-94.
[cited by applicant]
Yu et al., 2008 “Interaction between Bevacizumab and Murine VEGF-A: A Reassessment” Investigative Ophthalmology & Visual Science, 49(2):522-527.
[cited by applicant]
International Search Report issued Jul. 20, 2022 in connection with PCT/US2022/027413.
[cited by applicant]
Kolumam et al., 2015 “Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/BKlotho Complex” EBioMedicine, 2: 730-743.
[cited by applicant]
Wang et al., 2018 “IgG Fc engineering to modulate antibody effector functions” Protein & Cell 9(1):63-73.
[cited by applicant]
Written Opinion issued Jul. 20, 2022 In connection with PCT/US2022/027413.
[cited by applicant]
Yu Shi et al., 2018 “A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity” J Biol Chem 293(16)5909-5919.
[cited by applicant]
DeVay et al., 2017, “Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates,” Bioconjugate Chem. 28: 1102-1114.
[cited by applicant]